|
Deer Lake walkers double down on dialysis fundraiser - Tbnewswatch.com |
 |
 |
|
WINNIPEG -- By the time members of Deer Lake First Nation reached Winnipeg on foot Thursday, they realized their cause to bring a dialysis machine in their community had only begun to gain momentum.
On Saturday, they announced they're walking back to Thunder Bay.
Departing from the Lakehead on Aug. 10, the walk to bring awareness to the effects of remote health care on their community raised only $1,000 of the estimated $30,000 needed to bring a dialysis machine to Deer Lake, located 150 kilometres north of Red Lake.
"Even if we don't raise enough, we're happy we're making the journey," said walker and Deer Lake member, Marcus Meekis.
"Some people we know haven't seen their home in more than 15 years. We thought, 'how would I feel if I got taken out of my community and couldn't do the things I normally do, traditionally?' Can't go fishing, can't go hunting, can't go camping, can't enjoy the land.
"If a machine was there, at least they could come home and enoy their home, to go on a boat, to catch a fish in their own lakes."
Meekis said the growing attention over the course of the walk is beginning to show results in donations and although the four-person walking team never intended to walk back to Thunder Bay once they reached Winnipeg, they've decided to walk while the iron is hot.
"We're not oging to go door-to-door, putting people in a position where tehy have to answer you but it should come from how each person feels," he said.
"It's not about us. It's about trying to do something for our community, for our people who can't come home."
Deer Lake Chief Roy Dale Meekis traveled to Winnipeg to meet the walkers when they arrived. He praised the walkers for their efforts to increase the First Nation's health care capacity.
"High levels of diabetes and the lack of local access to treatment has caused a desperate situation for our community," the chief said.
"Our members who suffer from diabetes are forced to leave home for treatment and many never return."
|
|
Protein Irisin Linked to Muscle Wasting and Atherosclerosis in Dialysis Patients - Medical Research News and Interviews on MedicalResearch.com (blog) |
|
|
|
http://medicalresearch.com/heart-disease/protein-irisin-linked-to-muscle-wasting-and-atherosclerosis-in-dialysis-patients/16822/
MedicalResearch.com Interview with:
Tae-Hyun Yoo MD PhD
Department of Internal Medicine, College of Medicine
Severance Biomedical Science Institute, Brain Korea 21 PLUS
Yonsei University, Seoul, Korea
Medical Research: What is the background for this study? What are the main findings?
Dr.Tae-Hyun Yoo:Sarcopenia, reduction in muscle mass, is frequently observed in PEW and is prevalent in chronic kidney disease (CKD) patients. In ESRD patients, sarcopenia is significantly associated with greater mortality. Skeletal muscles produce and release myokines, which suggested to mediate their protective effects. Irisin, a novel myokine, has been introduced to drive brown-fat-like conversion of white adipose tissue and has beneficial effects of skeletal muscle on energy homeostasis and glucose metabolisms. Therefore, we hypothesized that irisin had significant association with sarcopenia and cardiovascular disease in dialysis patients. In peritoneal dialysis patients, serum irisin was positively correlated with mid-arm muscle circumference and thigh circumference. In addition, serum irisin was a significant independent predictor for carotid atherosclerosis even after adjustment for high-sensitivity C-reactive protein in these patients. This study demonstrated that serum irisin was significantly associated with sarcopenia and carotid atherosclerosis in peritoneal dialysis patients.
Medical Research: What should clinicians and patients take away from your report?
Dr.Tae-Hyun Yoo:Malnutrition and chronic inflammation have been proposed to explain the significant association between sarcopenia and cardiovascular disease in (end stage renal disease) ESRD population. Lower muscle mass might reflect poor nutritional status and higher degrees of unopposed inflammation. In addition to these factors, a myokine could be a contributor. In this study, irisin as a myokine could be helpful for stratifying risk of sarcopenia and carotid atherosclerosis in peritoneal dialysis patients. In addition, present study suggested muscle is an another important organ for protection and modulating cardiovascular diseases in dialysis population.
Medical Research: What recommendations do you have for future research as a result of this study?
Dr.Tae-Hyun Yoo:A study with follow-up carotid ultrasound and measurement of anthropometric indices and serum irisin is necessary to clarify the association of irisin, sarcopenia, and cardiovascular disease. Therefore, the impact of irisin on future cardiovascular outcomes should be clarified in the future study. The effect of the intervention using exercise training on irisin, sarcopenia, and cardiovascular disease might be also worth investigating in dialysis patients.
Citation:
Irisin, a novel myokine is an independent predictor for sarcopenia and carotid atherosclerosis in dialysis patients
Lee, Mi Jung et al. Atherosclerosis
Received: February 20, 2015; Received in revised form: July 7, 2015; Accepted: August 6, 2015; Published Online: August 13, 2015
Publication stage: In Press Accepted Manuscript
DOI: http://dx.doi.org/10.1016/j.atherosclerosis.2015.08.002
MedicalResearch.com is not a forum for the exchange of personal medical information, advice or the promotion of self-destructive behavior (e.g., eating disorders, suicide). While you may freely discuss your troubles, you should not look to the Website for information or advice on such topics. Instead, we recommend that you talk in person with a trusted medical professional.
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Tae-Hyun Yoo MD PhD (2015). Protein Irisin Linked to Muscle Wasting and Atherosclerosis in Dialysis Patients
|
|
|
Rockwell Medical Rating Reiterated by Oppenheimer (RMTI) - Dakota Financial News |
|
|
|
 Rockwell Medical (NASDAQ:RMTI)‘s stock had its “outperform” rating reiterated by investment analysts at Oppenheimer in a research note issued on Saturday, Analyst Ratings.Net reports. They currently have a $26.00 price objective on the stock. Oppenheimer’s target price points to a potential upside of 125.11% from the stock’s current price.
Rockwell Medical (NASDAQ:RMTI) opened at 11.55 on Friday. The stock’s 50 day moving average is $14.90 and its 200-day moving average is $12.18. The company’s market capitalization is $580.06 million. Rockwell Medical has a 1-year low of $8.10 and a 1-year high of $18.90.
Rockwell Medical (NASDAQ:RMTI) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.05) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.05. The firm had revenue of $12.96 million for the quarter, compared to analysts’ expectations of $11.84 million. During the same quarter in the previous year, the company posted ($0.08) EPS. The firm’s quarterly revenue was down .6% compared to the same quarter last year. On average, analysts expect that Rockwell Medical will post ($0.08) earnings per share for the current fiscal year.
Other equities analysts also recently issued research reports about the stock. TheStreet raised shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Brean Capital reaffirmed a “sell” rating and set a $4.00 price target on shares of Rockwell Medical in a research note on Friday, August 7th. Zacks cut shares of Rockwell Medical from a “buy” rating to a “hold” rating in a research report on Thursday, August 6th. Morgan Stanley began coverage on shares of Rockwell Medical in a report on Thursday, August 13th. They issued an “underweight” rating and a $7.00 price target on the stock. Finally, Bank of America reiterated a “neutral” rating and set a $18.00 price objective on shares of Rockwell Medical in a research note on Wednesday, July 8th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $18.00.
In other news, VP Raymond Dennis Pratt purchased 5,000 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was acquired at an average price of $11.54 per share, with a total value of $57,700.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Robert L. Chioini purchased 5,090 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was purchased at an average cost of $11.51 per share, with a total value of $58,585.90. The disclosure for this purchase can be found here.
Rockwell Medical, Inc. (NASDAQ:RMTI) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company’s lead branded drug, Triferic is approved by the United States Food and Drug Administration (FDA). Triferic is an iron compound that is delivered to hemodialysis patients via dialysate, replacing the iron loss that occurs during their dialysis treatment. Triferic enters the blood and immediately binds to transferrin and is transported to the erythroid precursor cells to be incorporated into hemoglobin. Rockwell’s generic drug, Calcitriol, is indicated for treating secondary hyperparathyroidism in dialysis patients. The Company manufactures, sells, delivers and distributes hemodialysis concentrates, along with a range of ancillary products.
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.
|
|
Volunteers sought for Beaver Dam Dialysis Center - Fond du Lac Reporter |
|
|
Ann Marie Dufrasne, left, a patient at the Beaver Dam Dialysis Center, is welcomed by William Nanney who was the first volunteer at the Beaver Dam Dialysis Center. The center is looking for other volunteers to help address patient comfort needs.(Photo: Photo courtesy of Agnesian HealthCare)
BEAVER DAM – For 13 years, the professionals with Agnesian HealthCare’s dialysis services in Beaver Dam have helped countless individuals experiencing kidney failure to receive quality, ongoing treatment at its Monroe Street facility.
Agnesian Dialysis Services offers two methods of treatment to people with end-stage kidney disease: Hemodialysis and peritoneal dialysis. Hemodialysis is a procedure, which uses a machine to rid the blood of waste buildup and remove excess water.
Peritoneal dialysis places fluid into the abdominal cavity to flush out the waste and excess water, which a functioning kidney would normally remove.
In addition, staff works with patients on renal (kidney) transplant options, including getting them on transplant waiting lists.
Patients and their families benefit from a multi-disciplinary team, including Drs. Bret Pasiuk and Rafal Ciecierski, both board-certified nephrologists. Dr. Pasiuk cares for patients in Beaver Dam and Fond du Lac, while Dr. Ciecierski sees patients in Fond du Lac and Waupun. They are joined by Aleshia Cole, APNP, nurse practitioner.
Working closely with these providers are Diane Posthuma and Sue VanHouten, dialysis supervisors, and a full complement of certified nurses and technicians. In addition, Agnesian Dialysis Services offers patients comprehensive support services from dietitians, social workers and chaplains who understand the special needs of patients on dialysis.
The dialysis center has added a new dimension to its care in Beaver Dam, and has found great success and is working to expand: Volunteers.
Volunteers are needed at the dialysis center on Tuesdays, Thursdays and Saturdays from 9:30 a.m. to noon. The ideal volunteer enjoys being around people, is a good listener and is detail-oriented to record patients’ weights. Interested individuals can choose to work one day per week or more.
For more information or to share interest in joining the dialysis team, contact Karen Gross at 920-324-6559 or complete an online application at agnesian.com.
Read or Share this story: http://fondul.ac/1JbzCcI
|
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
